August Buys: 4 Safer S&P 500 Dividend Dogs With Durability to Watch

August favors durable dividend income over the highest yields

Safer S&P 500 dividend dogs can pay you while the market catches up, but only if the payout is durable.

August looks useful for income investors because dividend stocks tracked the broad market in the first half before lagging as AI stocks revived. That backdrop offers another look at sturdy businesses before September and October volatility and before third-quarter earnings add more clarity.

The better trade is durability, not the highest yield. A high yield is not much help if it comes from a share price falling sharply. Investors still need proof that the payout is backed by operating cash, not just a cheaper stock. That is the real line between a safer dog and a yield trap.

Long dividend streaks can help, but they do not remove risk. Even respected dividend groups are not immune to dividend cuts, so a streak should start the review, not end it.

The four safer dogs all prioritize payout safety

The common thread is not sector. It is payout safety.

Realty Income: monthly dividends backed by a long raise streak

Realty Income fits the safer-dog profile because it is built around steady income delivery rather than speculation. It has increased its dividend for over 31 consecutive years, pays monthly dividends, and remains a member of the S&P 500 Dividend Aristocrats index. The model is straightforward: own a diversified commercial real-estate portfolio, collect rent, and pass along much of that steady cash flow on a monthly schedule. That structure can make the stock useful in a portfolio even when the yield is not the highest available.

The debate is familiar. Supporters see a proven landlord with a long operating history and a strong record of supporting the payout. Critics note that commercial real estate is rate-sensitive and that higher borrowing costs can pressure flexibility. That concern is reasonable, but it is not the same as saying the cash base has broken. The practical signals to watch are rent collection, how debt matures, and whether dividend growth remains intact.

Kimberly-Clark: consumer-staples durability with an approaching milestone

Kimberly-Clark is a different kind of safety. It is a household-name consumer staples business with a 50 or more consecutive years of dividend increases, and it sits among the 69 Dividend Aristocrats in 2026. That mix matters because the streak shows resilience through weaker cycles, while the current profile suggests the stock is not trading like a growth premium name.

The bull case is simple: people keep buying tissues, paper towels, and related products in most economic conditions. The counterpoint is that staples companies can get stuck in neutral if volumes soften or input costs stay heavy. The watchpoints are practical: unit sales, raw-material costs, margins, and the cash available to support the payout.

Medtronic: a mature medical-device leader with a larger payout

Medtronic's case is less about a headline yield streak and more about whether a mature healthcare leader can keep progressing after a tougher stretch. The current setup suggests a larger payout, which can support income-focused buyers, but it also leaves less flexibility if execution slips.

The bull case is that Medtronic still has durable products and recurring healthcare demand. The bear case is that a bigger payout leaves a narrower margin for error. The signals that matter most are therefore operational: hospital procedure volumes, guidance confidence, and whether management can grow the business without stretching the payout too far.

Clorox: a strong brand under pressure, close to King status

Clorox belongs on this list because it is nearing the 50-plus-year dividend increase milestone that would make it a Dividend King. Management has indicated it expects that status in 2026, and three more companies to be crowned as Dividend Kings in 2026 include Clorox. That milestone matters only if the business still looks healthy enough to support the streak.

Skeptics are right to flag private-label pressure and slower growth. Dividend history does not save a weak business model, and no-moat businesses are most likely to cut payouts. Clorox still appears to have enough brand strength and cash resilience to monitor closely, but the key questions remain market-share stability, pricing power, and whether the company can extend the streak without forcing the numbers.

How to evaluate these August dividend candidates

In August, the working rule is simple: buy the business first, the dividend second. That is the sensible response to a market where dividend stocks lagged as AI stocks revived. The opportunity is not in chasing the biggest yield sign. It is in owning a durable business after a weak quarter or muted tape.

What to monitor next

• Realty Income: Watch the operating backdrop behind dependable monthly dividends that grow over time, especially financing conditions, occupancy, and tenant health.
• Clorox: As Clorox moves closer to a possible Dividend King in 2026, the main tell is whether brand strength still shows up in pricing and share stability.
• Kimberly-Clark: The key question is whether everyday demand and margins still support the payout without obvious strain.
• Medtronic: This is mainly an execution watch. Focus on whether operations are stabilizing and whether the payout remains comfortably covered.

When the setup weakens

The view becomes less attractive if Realty Income's monthly income stability comes under financing or tenant pressure, if Clorox nears its milestone without pricing or share support, if Kimberly-Clark's streak survives while the business weakens, or if Medtronic's execution slips enough to narrow the payout cushion.

A streak is useful evidence, not a free pass. Even respected dividend groups are not immune to dividend cuts. Buy the operator first; if the business gets harder, a high yield is usually the warning, not the excuse.